Baxter InternationalMEX:BAX 44 Receivables Turnover is 1.52 as of Mar. 2026. GuruFocus rates MEX:BAX with a GF Score™ of 44/100 and a GF Value™ of MXN559.81 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Baxter International ranks better than 62.39% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Baxter International's Revenue for the
three
months ended in Mar. 2026 was MXN48,706 Mil. Baxter International's average Accounts Receivable for the
three
months ended in Mar. 2026 was MXN32,064 Mil.
Hence, Baxter International's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.52.
Baxter International (MEX:BAX) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Baxter International Receivables Turnover Related Terms
Baxter International Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Baxter International's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BAX vs ALGN, SOLV, COO: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Baxter International's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxter International Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Baxter International's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Baxter International (MEX:BAX) has a Receivables Turnover of 1.52 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Baxter International and its competitors. According to the industry distribution chart, Baxter International ranks #305 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 37.6%.
Is Baxter International's Receivables Turnover too high?
Baxter International's current Receivables Turnover is 1.52. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Baxter International's value of 1.52 is 72.4% below this industry median. Based on the distribution chart, Baxter International ranks #305 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Baxter International has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's Receivables Turnover compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #305 out of 811 companies for Receivables Turnover. This puts Baxter International in the upper half of its industry. The industry median Receivables Turnover is 5.51. Baxter International's value of 1.52 is 72.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baxter International's current Receivables Turnover of 1.52 is 72.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Baxter International and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current Receivables Turnover is 1.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (MEX:BAX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN559.81, compared to a current price of MXN368.00 — trading 34.3% below its estimated fair value. The current Receivables Turnover is 1.52 and 72.4% below the Medical Devices & Instruments industry median of 5.51. Baxter International's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Baxter International (MEX:BAX), the current Receivables Turnover is 1.52 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Baxter International (MEX:BAX) Overvalued in 2026?
Based on GuruFocus' analysis, Baxter International stock appears to be undervalued.
The current stock price of MXN368.00 is trading 34.3% below its estimated GF Value™ of MXN559.81.
GuruFocus considers Baxter International to be Possible Value Trap.
Key valuation signals for MEX:BAX:
Receivables Turnover: 1.52
GF Value™: MXN559.81 vs. price of MXN368.00 (34.3% below fair value)
Industry Position: 72.4% below the Medical Devices & Instruments median (#305 of 811)
No single metric tells the full story. See the MEX:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
44GF Score
Get the complete analysis for MEX:BAX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BAX has been successfully added to your 
